Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of some unusual options trading activity on Wednesday. Traders purchased 5,966 call options on the stock. This is an increase of 1,576% compared to the average volume of 356 call options.

FOLD has been the topic of several recent analyst reports. Leerink Swann reaffirmed a “buy” rating and set a $20.00 price objective (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Bank of America increased their price objective on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Chardan Capital reaffirmed a “buy” rating and set a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a report on Tuesday, October 10th. Finally, BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $17.81.

In other Amicus Therapeutics news, SVP Daphne Quimi sold 7,000 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $99,750.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Hung Do sold 50,194 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $715,264.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 826,114 shares of company stock worth $11,791,184. Insiders own 3.40% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of FOLD. Janus Henderson Group PLC acquired a new stake in shares of Amicus Therapeutics in the second quarter valued at about $70,762,000. Farallon Capital Management LLC acquired a new stake in shares of Amicus Therapeutics in the second quarter valued at about $30,210,000. Eagle Asset Management Inc. acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $40,450,000. Jennison Associates LLC raised its position in shares of Amicus Therapeutics by 9.4% in the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after buying an additional 838,267 shares during the last quarter. Finally, Allianz Asset Management GmbH acquired a new stake in shares of Amicus Therapeutics in the third quarter valued at about $11,381,000.

Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at $14.91 on Friday. The company has a market cap of $2,480.00, a PE ratio of -8.15 and a beta of 1.72. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics has a 12-month low of $5.07 and a 12-month high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million during the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. Amicus Therapeutics’s quarterly revenue was up 419.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.33) earnings per share. sell-side analysts anticipate that Amicus Therapeutics will post -1.56 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/amicus-therapeutics-target-of-unusually-high-options-trading-fold/1796658.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.